Literature DB >> 12957262

Influence of radiation therapy delay on abdominal tumor recurrence in patients with favorable histology Wilms' tumor treated on NWTS-3 and NWTS-4: a report from the National Wilms' Tumor Study Group.

John A Kalapurakal1, Sierra M Li, Norman E Breslow, J Bruce Beckwith, Roger Macklis, Patrick R M Thomas, Guilio J D'Angio, Tae Kim, Alfred de Lorimier, Panayotis Kelalis, Steven Shochat, Michael Ritchey, Gerald Haase, Ellen Hrabovsky, H Biemann Otherson, Paul Grundy, Daniel M Green.   

Abstract

PURPOSE: This study was undertaken to determine whether radiation therapy (RT) delay of >or=10 days had an adverse impact on abdominal tumor recurrence among children with favorable histology (FH) Wilms' tumor enrolled in National Wilms' Tumor Study (NWTS) 3 and 4. METHODS AND MATERIALS: A total of 1226 patients with Stage II-IV FH tumors who received flank or abdominal RT in NWTS-3 and NWTS-4 were included in this analysis. Recurrent disease in the operative bed was classified as flank recurrence. Abdominal recurrence included all infradiaphragmatic tumor recurrences, including flank recurrences. This analysis included all flank/abdominal tumor recurrences, regardless of whether they might have been the initial or subsequent site of relapse. Based on the NWTS-1 results, RT delay was analyzed in two categories: 0-9 days and >or=10 days.
RESULTS: The mean RT delay was 10.9 days; median delay was 9 days (range: 1-277 days). The RT delay was concentrated in a relatively narrow range of 8 to 12 days after nephrectomy in the majority of patients (59%). Univariate and multivariate analysis did not reveal RT delay of >or=10 days to significantly influence flank and abdominal tumor recurrence rates in NWTS-3 or NWTS-4. The 8-year flank tumor recurrence rates for 0-9 days and 10+ days RT delay were 1.9% and 1.2%, respectively (p value = 0.3). The 8-year abdominal tumor recurrence rates for 0-9 days and 10+ days RT delay were 4.8% and 5.3%, respectively (p value = 0.7).
CONCLUSIONS: RT delay of >or=10 days did not significantly influence flank or abdominal tumor recurrence rates among children with FH tumors treated on NWTS-3 and NWTS-4. However, we were unable to test for a meaningful difference, because of the concentration of RT delay close to 10 days.

Entities:  

Mesh:

Year:  2003        PMID: 12957262     DOI: 10.1016/s0360-3016(03)00598-4

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  7 in total

1.  Outcomes of children with favorable histology wilms tumor and peritoneal implants treated in National Wilms Tumor Studies-4 and -5.

Authors:  John A Kalapurakal; Daniel M Green; Gerald Haase; James R Anderson; Jeffrey S Dome; Paul E Grundy
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-06-01       Impact factor: 7.038

2.  Treatment of stage I anaplastic Wilms' tumour: a report from the Children's Oncology Group AREN0321 study.

Authors:  Najat C Daw; Yueh-Yun Chi; Yeonil Kim; Elizabeth A Mullen; John A Kalapurakal; Jing Tian; Geetika Khanna; James I Geller; Elizabeth J Perlman; Peter F Ehrlich; Anne B Warwick; Paul E Grundy; Conrad V Fernandez; Jeffrey S Dome
Journal:  Eur J Cancer       Date:  2019-07-17       Impact factor: 9.162

3.  Augmentation of Therapy for Combined Loss of Heterozygosity 1p and 16q in Favorable Histology Wilms Tumor: A Children's Oncology Group AREN0532 and AREN0533 Study Report.

Authors:  David B Dix; Conrad V Fernandez; Yueh-Yun Chi; Elizabeth A Mullen; James I Geller; Eric J Gratias; Geetika Khanna; John A Kalapurakal; Elizabeth J Perlman; Nita L Seibel; Peter F Ehrlich; Marcio Malogolowkin; James Anderson; Julie Gastier-Foster; Robert C Shamberger; Yeonil Kim; Paul E Grundy; Jeffrey S Dome
Journal:  J Clin Oncol       Date:  2019-08-26       Impact factor: 44.544

4.  Outcome and Prognostic Factors in Stage III Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group Study AREN0532.

Authors:  Conrad V Fernandez; Elizabeth A Mullen; Yueh-Yun Chi; Peter F Ehrlich; Elizabeth J Perlman; John A Kalapurakal; Geetika Khanna; Arnold C Paulino; Thomas E Hamilton; Kenneth W Gow; Zelig Tochner; Fredric A Hoffer; Janice S Withycombe; Robert C Shamberger; Yeonil Kim; James I Geller; James R Anderson; Paul E Grundy; Jeffrey S Dome
Journal:  J Clin Oncol       Date:  2017-12-06       Impact factor: 44.544

5.  Intraoperative spillage of favorable histology wilms tumor cells: influence of irradiation and chemotherapy regimens on abdominal recurrence. A report from the National Wilms Tumor Study Group.

Authors:  John A Kalapurakal; Sierra M Li; Norman E Breslow; J Bruce Beckwith; Michael L Ritchey; Robert C Shamberger; Gerald M Haase; Patrick R M Thomas; Paul Grundy; Daniel M Green; Giulio J D'Angio
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-01-01       Impact factor: 7.038

6.  Outcome of Children with Stage IV Wilms Tumor - Our Experience of 15 Years.

Authors:  Vishesh Jain; Anjan Dhua; Sandeep Agarwala; Sameer Bakhshi; M Srinivas; Venkateswaran K Iyer; Sandeep Mathur; Manisha Jana; Devasenathipathy Kandasamy; Ahitagni Biswas; Veereshwar Bhatnagar; Minu Bajpai
Journal:  J Indian Assoc Pediatr Surg       Date:  2020-10-27

7.  Is antenatal detection of Wilms tumor a bad prognostic marker.

Authors:  Vishesh Jain; Anup Mohta
Journal:  Indian J Med Paediatr Oncol       Date:  2013-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.